Gr1−/lowCD11b−/lowMHCII+ myeloid cells boost T cell anti-tumor efficacy

Kyle K. Payne, Hussein F. Aqbi, Savannah E. Butler, Laura Graham, Rebecca C. Keim, Wen Wan, Michael O. Idowu, Harry D. Bear, Xiang Yang Wang, Masoud H. Manjili

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Conventional APCs that express MHC class II (MHCII) and co-stimulatory molecules include dendritic cells (DCs) and macrophages. Beyond these conventional APCs, immune stimulatory cells have been more recently shown to extend to a class of atypical APCs, composed of mast cells, basophils, and eosinophils. Here, we describe a unique type of APC, Gr1−/lowCD11b−/low cells with a granularity and size characteristic of myeloid cells and with the ability to present Ag for crosspresentation. These cells constitutively express MHCII and the costimulatory molecules, CD80, CD86, and CD40. They do not express pan markers of myeloid DCs (CD11c), plasmacytoid DCs (Ly6C), or macrophages (F4/80), and their frequency is inversely correlated with myeloid-derived suppressor cells (MDSCs) in tumor-bearing mice. Among splenocytes, they are more abundant than DCs and macrophages, and they exhibit antitumor immune stimulatory function at a steady state without further activation, ex vivo. They are also found within the tumor bed where they retain their immune stimulatory function. Our findings suggest the use of these novel APCs in additional preclinical studies to further investigate their utility in APC-based cancer immunotherapies.

Original languageEnglish (US)
Pages (from-to)1215-1228
Number of pages14
JournalJournal of Leukocyte Biology
Issue number6
StatePublished - Dec 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Cell Biology


  • Ag presenting cells
  • adoptive immunotherapy
  • breast cancer
  • cancer vaccine
  • myeloid-derived suppressor cells


Dive into the research topics of 'Gr1−/lowCD11b−/lowMHCII+ myeloid cells boost T cell anti-tumor efficacy'. Together they form a unique fingerprint.

Cite this